Obsidian Therapeutics, Inc. (OBX) News
Follow Obsidian Therapeutics, Inc. (OBX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Obsidian Therapeutics initiated at Outperform by William Blair
William Blair initiated coverage of Obsidian Therapeutics with an Outperform rating, per Benzinga ratings actions.
EQUITY | Sep 09, 2026, 08:45 PM UTC
L
Obsidian Therapeutics files prospectus for resale of up to 29,164,045 shares
Obsidian Therapeutics filed a prospectus covering the resale of up to 29,164,045 shares of common stock by selling stockholders.
REGULATION | Aug 28, 2026, 09:16 PM UTC